anti-CTLA-4 antibody · antibody

tremelimumab

3 active trials across 5 of our biomarkers, targeting CTLA-4. Not approved for any biomarker on marked.bio yet.

Also known as CP-675,206, Imjudo.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

Biomarker	Active trials	All trials	Furthest active phase
BRCA1/2 mutation	1	2	Phase 1/2
KRAS G12C	1	2	Phase 2
KRAS G12D	1	2	Phase 2
MSI-H / dMMR	1	2	Phase 1/2
EGFR exon 19 deletion / L858R	0	2	–

Trials

3 of 8 trials shown

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Active, not recruiting Phase 2 AstraZeneca Started 2024Primary completion 2026-10 NCT06008093

durvalumabtremelimumabpemetrexedpembrolizumabcarboplatincisplatin

Participants must have tumors with STK11 or KEAP1 or KRAS mutations.

KRAS G12CKRAS G12DCarcinoma, Non-Small-Cell Lung
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Recruiting Phase 1/2 Anwaar Saeed Started 2018Primary completion 2028-06 NCT03539822

cabozantinibdurvalumab FDA EUtremelimumab

Patients should have known tumor results for microsatellite instability (MSI) or mismatch repair (MMR) proteins.

MSI-H / dMMRGastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Active, not recruiting Phase 1/2 New Mexico Cancer Research Alliance Started 2016Primary completion 2020-12 NCT02571725

olaparib FDA EUtremelimumab

Patients must have a confirmed germline mutation in the BRCA1 or BRCA2 gene

BRCA1/2 mutationOvarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Unknown status Phase 2 University of Sydney Started 2018 NCT03994393

tremelimumabdurvalumab

…/or cytologically confirmed non-squamous non-small cell lung cancer with EGFR mutation of Exon 19 deletion or Exon 21 L858R point mutation.

EGFR exon 19 deletion / L858REGFR Mutant Advanced Non Small Cell Lung Cancer
Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC

Completed Phase 1/2 Centre Georges Francois Leclerc Started 2017 NCT03202758

durvalumabtremelimumabFOLFOX

Histologically confirmed diagnoses of colorectal cancer with positive mutated KRas.

KRAS G12CKRAS G12DColorectal Cancer Metastatic
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Completed Phase 2 Roswell Park Cancer Institute Started 2017 NCT02953457

durvalumabolaparib FDA EUtremelimumab

A germline BRCA1 or BRCA2 deleterious alteration.

BRCA1/2 mutationBRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Completed Phase 2 Memorial Sloan Kettering Cancer Center Started 2017 NCT03015129

durvalumab FDA EUtremelimumab

MSI-high patients will be identified based on immunohistochemistry or MSI testing of archival tumo…

MSI-H / dMMREndometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

Completed Phase 1 Gustave Roussy, Cancer Campus, Grand Paris Started 2014 NCT02040064

gefitinib FDA EUtremelimumab

…tivating EGFR TK mutations known to be associated with EGFR TKI sensitivity (i.e., G719X, exon 19 deletion, L858R, L861Q) as determined locally using a well-validated and robust methodology ;

EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

Biomarkers

Sponsors

Trials